What is Glucagon? Glucagon is a hormone that helps the liver release glucose to raise blood glucose levels. It can be administered through injection, auto-injection pen or nasal spray. Glucagon […]
Changes to Glucagon Availability in Canada
CanScreenT1D: Screening Research Consortium in Canada Announced
JDRF Canada, in collaboration with CIHR, is thrilled to announce the recipients of the CIHR-JDRF Type 1 Diabetes Screening Research Consortium. This $12 million grant will develop a single nationally […]
Exciting updates from Vertex stem cell-based therapy clinical trials
A large area of cure-based T1D research is investigating stem cell-based therapy. The goal of this approach is to use stem cells as a renewable source of insulin-producing cells which, […]
JDRF Golf Challenge
The name Garfinkle is synonymous with JDRF Canada. Over 50 years ago, in 1971 and 1973 respectively, Krayna Golfman and Mitch Garfinkle saw their sons, David and Jimmy diagnosed with […]
New Drug to Prevent Hypoglycemia Enters Clinical Trials
Low blood sugar, called hypoglycemia, is a real fear for people with type 1 diabetes (T1D). Although there are rescue treatments for it, such as injectable or nasal glucagon (Baqsimi), there are currently no preventive therapies available. Canadian company Zucara Therapeutics, however, may have an answer.
The U.S. Food and Drug Administration clears a new artificial pancreas system
On May 23, 2023 the U.S. Food and Drug Administration (FDA) cleared the iLet® Insulin-Only Bionic Pancreas System for people 6 years of age and older with type 1 diabetes […]
JDRF 2023 Innovation Grants
JDRF provides seed funding for highly innovative research with significant potential to accelerate the most promising type 1 diabetes (T1D) research in both cures and approaches to improve disease management. […]
Meet our new Board Chair – Helena Gottschling
In late April 2023, Helena Gottschling was elected Board Chair for JDRF Canada. Helena Gottschling is a purpose-driven leader who enjoyed a 37-year career with RBC before retiring in 2022. […]
JDRF-CIHR Mental Health Grants
Mental health and psychosocial issues remain an under-researched yet frequent aspect of living with type 1 diabetes (T1D). As part of the JDRF-CIHR Partnership to Defeat Diabetes, JDRF is pleased […]
Mental Health and Diabetes – where JDRF is today
May is Mental Health Awareness month, a national movement to raise awareness of the importance of mental health, and the structural gaps that exist in accessing treatment and support. There […]
JDRF International Collaboration Leads to Next-Generation Cell Therapy Research
JDRF Canada and all JDRF affiliates are committed to supporting the development of cell replacement therapies that will one day offer cures for type 1 diabetes (T1D). T1D is an […]
Clinical Trials
In addition to funding critical type 1 diabetes (T1D) clinical trials, a key focus for JDRF is increasing awareness of and participation in trials. All new interventions, from drugs to […]
